Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Ninth informational Supplement: M100-S9. NCCLS, Wayne, PA, 1999.
[2.]
J.H. Jorgensen, A.W. Howell, L.A. Maher.
Cuantitative antimicrobial susceptibility testing of Haemophilus influenzae and Streptococcus pneumoniae by using the E-test.
J Clin Microbiol, 29 (1991), pp. 109-114
[3.]
F.S. Nolte, B. Metchock, T. Williams, L. Diem, A. Bressler, F.C. Tenover.
Detection of penicillin resistant Streptococcus pneumoniae with commercially available broth microdilution panels.
J Clin Microbiol, 33 (1995), pp. 1.804-1.806
[4.]
L.L. Guthrie, S. Banks, W. Setiawan, K.B. Waites.
Comparison of MicroScan MICroSTREP, PASCO, and Sensititre MIC panels for determining antimicrobial susceptibilities of Streptococcus pneumoniae.
Diagn Microbiol Infect Dis, 33 (1999), pp. 267-273
[5.]
R. Hakenbeck, M. Tarpay, A. Tomasz.
Multiple changes of penicillin-binding proteins in penicillin-resistant clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother, 17 (1980), pp. 364-371
[6.]
R. Muñoz, C.G. Dowson, M. Daniels, T.J. Coffey, C. Martin, R. Hakenbeck, et al.
Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae.
Mol Microbiol, 6 (1992), pp. 2.461-2.465
[7.]
R. Leclercq, P. Courvalin.
Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification.
Antimicrob Agents Chemother, 35 (1991), pp. 1.267-1.272
[8.]
A. Tait-Kamradt, J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, et al.
MefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.
Antimicrob Agents Chemother, 41 (1997), pp. 2.251-2.255
[9.]
J. Sutcliffe, A. Tait-Kamradt, L. Wondrack.
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.
Antimicrob Agents Chemother, 40 (1996), pp. 1.817-1.824
[10.]
K. Waites, C. Johnson, B. Gray, K. Edwards, M. Crain, W. Benjamin.
Use of clindamycin disks to detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children.
J Clin Microbiol, 38 (2000), pp. 1.731-1.734
[11.]
Pérez-Trallero E, Bouza E, García de Lomas J, García-Rodríguez JA,García-Rey C and the Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial susceptibility of 1,685 Streptococcus pneumoniae isolates from respiratory infections in Spain (1998-1999). En: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000.
[12.]
A. Marchese, E. Tonoli, E.A. Debbia, G.C. Schito.
Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy.
J Antimicrob Chemother, 44 (1999), pp. 461-464
[13.]
A. Tait-Kamradt, T. Davies, P.C. Appelbaum, F. Depardieu, P. Courvalin, J. Petitpas, et al.
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.
Antimicrob Agents Chemother, 44 (2000), pp. 3.395-3.401
[14.]
A. Luttinger.
The twisted life of DNA in the cell: Bacterial topoisomerases.
Mol Microbiol, 15 (1995), pp. 601-606
[15.]
C. Janoir, V. Zeller, M.D. Kitzis, N.J. Moreau, L. Gutmann.
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutation in parC and gyrA.
Antimicrob Agents Chemother, 40 (1996), pp. 2.760-2.764
[16.]
E. Varon, L. Gutmann.
Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae.
Res Microbiol, 15 (2000), pp. 471-473
[17.]
A. Fenoll, I. Jado, D. Vicioso, A. Pérez, J. Casal.
Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: Update (1990 to 1996).
J Clin Microbiol, 36 (1998), pp. 3.447-3.454
[18.]
F. Baquero, J.A. García-Rodríguez, J. García de Lomas, L. Aguilar.
the Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study.
Antimicrob Agents Chemother, 43 (1999), pp. 357-359
[19.]
R.V. Kies, A. Siedler, H.J. Schmitt, R.R. Reinert.
Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines.
Clin Infect Dis, 31 (2000), pp. 482-487
[20.]
M.A. Sempere, J. Gómez, J. Ruiz.
Resistance of Streptococcus pneumoniae to erythromycin in adults and children.
J Antimicrob Chemother, 29 (1992), pp. 348-349
[21.]
J. Ruiz, M.L. Núñez, J. Díaz, J. Gómez, F. Luengo-Martín.
Resistencia de Streptococcus pneumoniae a eritromicina en la comunidad de Murcia.
Rev Esp Quimioterap, 7 (1994), pp. 224-227
[22.]
B.L. Lee, A.M. Padula, R.C. Kimbrough, S.R. Jones, R.E. Chaisson, J. Mills, et al.
Infectious complications with respiratory pathogens despite ciprofloxacin therapy.
N Engl J Med, 325 (1991), pp. 520-521
[23.]
S. Rittenhouse, L. McCloskey, J. Broskey, N. Niconovich, C. Jakielaszek, J. Poupard, et al.
In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
J Antimicrob Chemother, 45 (2000), pp. 23-27
[24.]
D.B. Hoellman, G. Lin, M.R. Jacobs, P.C. Appelbaum.
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
J Antimicrob Chemother, 43 (1999), pp. 645-649
[25.]
J.D. Knudsen, K. Fuursted, F. Espersen, N. Frimodt-Moller.
Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.
Antimicrob Agents Chemother, 41 (1997), pp. 1.910-1.915
[26.]
J. Liñares, T. Alonso, J.L. Pérez, J. Ayats, M.A. Domínguez, R. Pallarés, et al.
Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics.
J Antimicrob Chemother, 30 (1992), pp. 279-288
[27.]
J. Ruiz, M. Sempere, E. Simarro, A. Fenoll.
Description of two new isolates of Streptococcus pneumoniae in Spain that are highly resistant to cefotaxime.
Antimicrob Agents Chemother, 42 (1998), pp. 2.768-2.769
[28.]
L.M. Ednie, M.A. Visalli, M.R. Jacobs, P.C. Appelbaum.
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
Antimicrob Agents Chemother, 40 (1996), pp. 1.950-1.952
[29.]
I.R. Friedland, K.P. Klugman.
Antibiotic-resistant pneumococcal disease in South African children.
Am J Dis Child, 146 (1992), pp. 920-923
[30.]
R. Pallarés, J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, P.F. Viladrich, et al.
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
N Engl J Med, 333 (1995), pp. 474-480
[31.]
R.J. Leggiadro.
The clinical impact of resistance in the management of pneumococcal disease.
Infect Dis Clin North Am, 11 (1997), pp. 867-874
[32.]
E. Simarro, J. Ruiz.
Resistencia de Streptococcus pneumoniae a los antibióticos.
Rev Esp Quimioterap, 11 (1998), pp. 353-355
[33.]
R. Pallarés.
Treatment of pneumococcal pneumonia.
Semin Respir Infect, 14 (1999), pp. 276-284
[34.]
J.D. Heffelfinger, S.F. Dowell, J.H. Jorgensen, K.P. Klugman, L.R. Mabry, D.M. Musher, et al.
Management of community-adquired pneumonia in the era of pneumococcal resistance.
Arch Intern Med, 160 (2000), pp. 1.399-1.408
[35.]
C. Carbon, M.D. Poole.
The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
J Chemother, 11 (1999), pp. 107-118
[36.]
M. Aubier, H. Lode, G. Gialdroni-Grassi, G. Huchon, J. Hosie, N. Legakis, et al.
Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
J Antimicrob Chemother, 37 (1996), pp. 73-82
[37.]
W.A. Craig.
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
Clin Infect Dis, 26 (1998), pp. 1-10
[38.]
J.G. Bartlett, R.F. Breiman, L.A. Mandell, T.M. File.
Community-acquired pneumonia in adults: guidelines for management.
Clin Infect Dis, 26 (1998), pp. 811-838
[39.]
J. Frías, M. Gomis, J. Prieto, J. Mensa, E. Bouza, J.A. García-Rodríguez, et al.
Tratamiento antibiótico empírico inicial de la neumonía adquirida en la comunidad.
Rev Esp Quimioterap, 11 (1998), pp. 255-261
[40.]
J. Gómez, V. Baños, J. Ruiz Gómez, F. Herrero, M.L. Núñez, M. Canteras, et al.
Clinical significance of pneumococcal bacteremias in a general hospital: a prospective study 1989-1993.
J Antimicrob Chemother, 36 (1995), pp. 1.021-1.030
[41.]
J.M. Nava, F. Bella, J. Garau, J. Lite, M.A. Morera, C. Marti, et al.
Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study.
Clin Infect Dis, 19 (1994), pp. 884-890
[42.]
S.B. Mannheimer, L.W. Riley, R.B. Roberts.
Association of penicillin-resistant pneumococci with residence in a pediatric chronic care facility.
J Infect Dis, 174 (1996), pp. 513-519
[43.]
J.P. Bedos, S. Chevret, C. Chastang, P. Geslin, B. Regnier.
Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey.
Clin Infect Dis, 22 (1996), pp. 63-72
[44.]
S.L. Kaplan, E.O. Mason.
Management of infections due to antibiotic-resistant Streptococcus pneumoniae.
Clin Microbiol Rev, 11 (1998), pp. 628-644
[45.]
R. Pallarés, O. Capdevila, I. Grau.
Treatment options for resistant pneumococcal infections.
Clin Microbiol Infect, 5 (1999),
[46.]
O. Ruuskanen, J. Mertsola.
Childhood community-adquired pneumonia.
Semin Respir Infect, 14 (1999), pp. 163-172
[47.]
T. Heiskanen-Kosma, M. Korppi, C. Jokinen, S. Kurbi, L. Heiskanen, H. Juvonen, et al.
Etiology of childhood pneumonia: aerologic results of a prospective,population-based study.
Pediatr Infect Dis J, 17 (1998), pp. 986-991
[48.]
L. Wubbel, L. Muniz, A. Ahmed, M. Trujillo, C. Carubelli, C. McCoig, et al.
Etiology and treatment of community-acquired pneumonia in ambulatory children.
Pediatr Infect Dis J, 18 (1998), pp. 98-104
[49.]
I.R. Friedland.
Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease.
Pediatr Infect Dis J, 14 (1995), pp. 885-890
[50.]
T.Q. Tan, E.O. Mason, W.J. Barson, E.R. Wald, G.E. Schutze, J.S. Bradley, et al.
Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae.
Pediatrics, 102 (1998), pp. 1.369-1.375
[51.]
U.B. Schaad, G.H. McCracken, C.A. Loock, M.L. Thomas.
Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
J Infect Dis, 143 (1998), pp. 1.369-1.375
[52.]
G.W. Amsden, J.J. Schentag.
Tables of antimicrobial agent pharmacology.
Principles and practice of infectious diseases, (4th ed.), pp. 492-528
[53.]
M.J. Catalán, J.M. Fernández, A. Vázquez, E.V. Seijas, A. Suárez, J.C.L.B. Quirós.
Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae.
Clin Infect Dis, 18 (1994), pp. 766-769
[54.]
C.C. John.
Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.
Clin Infect Dis, 18 (1994), pp. 188-193
[55.]
M.M. Sloas, F.F. Barrett, P.J. Chesney, B.K. English, B.C. Hill, F.C. Tenover, et al.
Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis.
Pediatr Infect Dis J, 11 (1992), pp. 662-666
[56.]
M.E. Pichichero.
Recurrent and persistent otitis media.
Pediatr Infect Dis J, 19 (2000), pp. 911-916
[57.]
W.A. Craig, D. Andes.
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.
Pediatr Infect Dis J, 15 (1996), pp. 255-259
[58.]
J.L. Blumer.
Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media.
Pediatr Infect Dis J, 17 (1998), pp. 1.070-1.075
[59.]
S.F. Dowell, J.C. Butler, G.S. Giebink, M.R. Jacobs, D. Jernigan, D.M. Musher, et al.
Acute otitis media: a management and surveillance in an era of pneumococcal resistance- a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.
Pediatr Infect Dis J, 18 (1999), pp. 1-9
[60.]
C.T. Nelson, E.O. Mason, S.L. Kaplan.
Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment.
Pediatr Infect Dis J, 13 (1994), pp. 585-589
[61.]
C.J. Harrison.
Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy.
Pediatr Infect Dis J, 16 (1997), pp. S12-S16
[62.]
A.L. Barry, P.C. Fuchs, S.D. Brown.
Antipneumococcal activities of a ketolide (HMR 3647), a Streptogramin (Quinupristin-Dalfopristin), a macrolide (Erythromycin), and a lincosamide (Clindamycin).
Antimicrob Agents Chemother, 42 (1998), pp. 945-946
Copyright © 2001. Elsevier España, S.L.. All rights reserved
